The major financial objective of the current position due to Family relation is the Shipowning Business in particularly the Asset Playing in the Shipping Industry. The current activity includes the Private Funding of Ship and Offshore Investment Projects in the Shipping Syndicated Market.Alternative Credit Asset Classes especially of Opportunistic and Special Situations character in Innovative Investment Schemes in Health Care Sector including Biotechnology, Pharmaceuticals and Life Sciences Industries as well as Specialized Finance and Aviation Industries are of predominant interest.Especially, his tight relation to the Academic Environment of Columbia University through his position as an Assistant Professor intrigued his interest, especially for Pharmaceutical & Life Sciences Investment Projects.All the information provided here is addressed only to Institutional Investors.These Investing Activities are facilitated through his Membership in the most Prestigious and Exclusive Premier Private Members' Clubs around the world, mainly in the Unites States.Important Notes: * According to Online Mendelian Inheritance in Man (OMIM); National Institutes of Health (NIH); National Center for Biotechnology Information (NCBI); National Library of Medicine (an Official website of the United States Government) there are 10 References in this site under his name. H. Houston Merrit Clinical Research Center for Muscular Dystrophy and Related Diseases. Department of Neurology. Columbia University.* Professor Karadimas has an activated account only on LinkedIn and in no other Social Media or Artificial Intelligence generated podcasts or anything related to them. Due to security reasons the Publicity of Prof. Karadimas personal information is restricted only in his LinkedIn Profile. * The return in Academic research has been postponed due to Family reasons. There is an offer to collaborate with a prestigious University as Professor from the Academic year 2027-2028. Meanwhile, for the next two years he and his Business Partners will exclusively organize their new Business Ventures. He will be overseas until the end of January 2025 for Business reasons.*For more Scientific Information, please search in Google Scholar and National Center for Biotechnology Information (NCBI; PubMed; an Official website of the United States Government) under the term "Karadimas Charalampos".